Merz Therapeutics completed the acquisition of Acorda Therapeutics for $185m.

Merz Therapeutics, a neurological disorders pharmaceutical company, completed the acquisition of Acorda Therapeutics, an American biotechnology company for $185m. “The addition of INBRIJA and (F)AMPYRA to the treatment portfolio underlines Merz Therapeutics’ global Pivot for Growth strategy to both evolve the current portfolio and achieve critical scale and global reach. Merz Therapeutics is well poised to build on what we have accomplished in the specialty neurology space, strengthening our market position in Parkinson’s disease and expanding into the MS segment. This deal demonstrates Merz Therapeutics’ interest and ability to acquire assets that will deliver greater, sustainable outcomes for more people living with neurological disorders,” Stefan König, Merz Therapeutics CEO.